<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03509207</url>
  </required_header>
  <id_info>
    <org_study_id>SAHA</org_study_id>
    <nct_id>NCT03509207</nct_id>
  </id_info>
  <brief_title>Vorinostat (SAHA) in Uterine Sarcoma</brief_title>
  <official_title>A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uterine sarcomas are rare tumors with a poor prognosis.

      The main purpose of this phase II proof-of-principle- pilot study is to test the efficacy of
      the hydroxamic acid-based Histone deacetylase inhibitor (HDACI) Vorinostat (SAHA) as
      monotherapy in patients with HDAC-positive, progressive, metastatic uterine sarcomas and
      mixed epithelial and mesenchymal tumors after prior anti-proliferative therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single arm, proof of concept-study of the HDAC-inhibitor vorinostat in
      patients with refractory uterine sarcoma that have been pre-tested for an high expression of
      HDAC. Patients will receive Vorinostat, 400 mg (4 capsules á 100mg of Zolinza) orally once
      daily for the first 14 days of a 21 day cycle. Treatment will be continued for 4 cycles
      (treatment period 1). Patients with a response or stable disease after 4 cycles as determined
      by computed tomography (CT) of target an non target-lesions will be continued on vorinostat
      therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity
      or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be
      administered over a 9 months period (treatment periods 2 and 3).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The early termination was NOT due to safety reasons, terminated because of the very slow
    recruitment and problematic access to the study medication in Europe
  </why_stopped>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Actual">February 4, 2019</completion_date>
  <primary_completion_date type="Actual">February 4, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>9 months</time_frame>
    <description>Change from Baseline Tumor Size to last available observation with respect to progress as defined by RECIST 1.1 (CT-Scan every 12 weeks up to 9 months)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>9 months</time_frame>
    <description>This endpoint is evaluated by the amount of clinical adverse experiences.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Leiomyosarcoma</condition>
  <condition>Endometrial Stromal Tumors</condition>
  <condition>Carcinosarcomas Uterine</condition>
  <arm_group>
    <arm_group_label>Vorinostat, Zolinza Oral Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vorinostat Oral Capsules 400mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vorinostat Oral Capsule</intervention_name>
    <description>Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients' withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.</description>
    <arm_group_label>Vorinostat, Zolinza Oral Capsules</arm_group_label>
    <other_name>Zolinza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed metastatic uterine sarcoma (endometrial stromal sarcoma,
             undifferentiated uterine sarcoma, leiomyosarcoma, adenosarcoma and carcinosarcoma

               -  High HDAC-positivity of the tumor determined by immunohistochemistry

               -  Patients must have received prior systemic antineoplastic therapy

               -  Patient is not amenable for curative therapy

               -  Age &gt;= 18 years

               -  Estimated life expectancy &gt; 3 months

               -  Measurable disease on CT/MRI (at least one measurable lesion &gt;1cm) or chest X-ray
                  (at least one measurable lesion &gt;2cm)

               -  Karnofsky performance status of 60-100

               -  Adequate hematologic, renal and hepatic function

               -  Subject is able to swallow and retain oral medication and does not have
                  uncontrolled emesis

               -  No fertility preserved

               -  Written informed consent

        Exclusion Criteria:

          -  Lack of or low expression of HDAC (see 4.1 &quot;Pre-Screening&quot;)

               -  Significant cardiac disease

               -  Other invasive malignant tumor diagnosed within the last 5 years (e.g. metastases
                  from breast cancer in the last 3 years)

               -  Significant bowel obstruction

               -  Severe uncontrolled infection

               -  Known HIV-positivity

               -  Symptomatic brain metastasis or leptomeningeal disease

               -  Pre-existing significant liver disease, severe hepatic impairment (Bilirubin no
                  greater than 1.5 times upper limit of normal (ULN) and/or aspartate
                  aminotransferase (AST)/ alanine aminotransferase (ALT) greater than 2.5 times
                  ULN)

               -  Known history of allergic reaction to vorinostat or similar medications

               -  Systemic therapy or an investigational agent within 21 days prior to study
                  inclusion

               -  Uncontrolled hypertension (sustained systolic blood pressure &gt; 150 mmHg or
                  diastolic pressure &gt; 100 mmHg despite optimal medical management)

               -  Major surgery within 3 weeks of enrollment when diagnosed at an early stage

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris or cardiac arrhythmia

               -  Myocardial infarction within last 6 months

               -  Known active hepatitis B or hepatitis C

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements-

               -  Prior history of thrombotic or thromboembolic events, unless adequately
                  controlled by anticoagulant therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>The investigated condition occurs exclusively in women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edgar Petru, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of OB/GYN of the Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz, Clinic of Obstetrics and Gynecology</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <results_first_submitted>July 9, 2020</results_first_submitted>
  <results_first_submitted_qc>July 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 27, 2020</results_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine sarcoma</keyword>
  <keyword>Histone deacetylases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Leiomyosarcoma</mesh_term>
    <mesh_term>Carcinosarcoma</mesh_term>
    <mesh_term>Mixed Tumor, Mullerian</mesh_term>
    <mesh_term>Endometrial Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 22, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03509207/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>3 patients were enrolled. The study was prematurely closed due to the sluggish patient recruitment and the difficult acquisition of the investigational product.</recruitment_details>
      <pre_assignment_details>There were no Screening failures in the Course of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vorinostat, Zolinza Oral Capsules</title>
          <description>Vorinostat Oral Capsules 400mg daily
Vorinostat Oral Capsule: Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients’ withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Statistical evaluation was not possible as only 1 Patient reached end point 1.</population>
      <group_list>
        <group group_id="B1">
          <title>Vorinostat, Zolinza Oral Capsules</title>
          <description>Vorinostat Oral Capsules 400mg daily
Vorinostat Oral Capsule: Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients’ withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Change from Baseline Tumor Size to last available observation with respect to progress as defined by RECIST 1.1 (CT-Scan every 12 weeks up to 9 months)</description>
        <time_frame>9 months</time_frame>
        <population>Only one Patient reached the first end Point. Statistical Evaluation was therefore not possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat, Zolinza Oral Capsules</title>
            <description>Vorinostat Oral Capsules 400mg daily
Vorinostat Oral Capsule: Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients’ withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Change from Baseline Tumor Size to last available observation with respect to progress as defined by RECIST 1.1 (CT-Scan every 12 weeks up to 9 months)</description>
          <population>Only one Patient reached the first end Point. Statistical Evaluation was therefore not possible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</title>
        <description>This endpoint is evaluated by the amount of clinical adverse experiences.</description>
        <time_frame>9 months</time_frame>
        <population>Only one Patient reached the first end Point. Statistical Evaluation was therefore not possible.</population>
        <group_list>
          <group group_id="O1">
            <title>Vorinostat, Zolinza Oral Capsules</title>
            <description>Vorinostat Oral Capsules 400mg daily
Vorinostat Oral Capsule: Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients’ withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)</title>
          <description>This endpoint is evaluated by the amount of clinical adverse experiences.</description>
          <population>Only one Patient reached the first end Point. Statistical Evaluation was therefore not possible.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrolment to study completion per Patient.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vorinostat, Zolinza Oral Capsules</title>
          <description>Vorinostat Oral Capsules 400mg daily
Vorinostat Oral Capsule: Vorinostat, 400 mg orally once daily for the first 14 days of a 21 day cycle Treatment will be continued for 4 cycles. Patients with a response or stable disease after 4 cycles will be continued on vorinostat therapy at the tolerated schedule and dosage until disease progression, unacceptable toxicity or patients’ withdrawal of the consent. At the maximum, a total of 12 cycles will be administered over a period of 9 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Death of uterine carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>abscess of the vaginal vault</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Edgar Petru</name_or_title>
      <organization>Medical University of Graz</organization>
      <phone>0043 31638581082</phone>
      <email>edgar.petru@medunigraz.at</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

